In vivo kinetic approach reveals slow SOD1 turnover in the CNS

Journal of Clinical Investigation

Volumn 125, Issue 7, 2015, Pages 2772-2780

  Crisp, Matthew J ^a   Mawuenyega, Kwasi G ^a   Patterson, Bruce W ^a   Reddy, Naveen C ^a   Chott, Robert ^a   Self, Wade K ^a   Weihl, Conrad C ^a   Jockel Balsarotti, Jennifer ^a   Varadhachary, Arun S ^a   Bucelli, Robert C ^a   Yarasheski, Kevin E ^a   Bateman, Randall J ^a   Miller, Timothy M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13 LEUCINE; COPPER ZINC SUPEROXIDE DISMUTASE; TRACER; UNCLASSIFIED DRUG; CARBON; MUTANT PROTEIN; RECOMBINANT PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME KINETICS; ENZYME METABOLISM; FEMALE; HALF LIFE TIME; HUMAN; IMMUNOPRECIPITATION; IN VIVO STUDY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT; SPINAL CORD; TANDEM MASS SPECTROMETRY; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; KINETICS; METABOLISM; MOLECULAR GENETICS; SITE DIRECTED MUTAGENESIS; TRANSGENIC RAT;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CARBON ISOTOPES; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; FEMALE; HEK293 CELLS; HUMANS; ISOTOPE LABELING; KINETICS; MALE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; RATS; RATS, TRANSGENIC; RECOMBINANT PROTEINS; SUPEROXIDE DISMUTASE; TANDEM MASS SPECTROMETRY;

EID: 84936804907     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80705     Document Type: Article

References (40)

1. Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.
2. Worms PM. The epidemiology of motor neuron diseases: A review of recent studies. J Neurol Sci. 2001;191(1):3-9.
3. Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17(18):1942-119.
4. Price JC, Guan S, Burlingame A, Prusiner SB, Ghaemmaghami S. Analysis of proteome dynamics in the mouse brain. Proc Natl Acad Sci U S A. 2010;107(32):14508-14513.
5. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12(7):856-861.
6. Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom. 2007;18(6):997-1006.
7. Elbert DL, Mawuenyega KG, Scott EA, Wildsmith KR, Bateman RJ. Stable isotope labeling tandem mass spectrometry (SILT): integration with peptide identification and extension to data-dependent scans. J Proteome Res. 2008;7(10):4546-4556.
8. Bateman RJ, et al. A γ-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66(1):48-54.
9. Mawuenyega KG, et al. Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science. 2010;330(6012):1774.
10. Castellano JM, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3(89):89ra57.
11. Potter R, et al. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5(189):189ra177.
12. Mawuenyega KG, Kasten T, Sigurdson W, Bateman RJ. Amyloid-β isoform metabolism quantitation by stable isotope-labeled kinetics. Anal Biochem. 2013;440(1):56-62.
13. Fanara P, et al. Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J Clin Invest. 2012;122(9):3159-3169.
14. Price JC, et al. Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry. Anal Biochem. 2012;420(1):73-83.
15. Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59-62.
16. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969;244(22):6049-6055.
17. Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435-442.
18. Foust KD, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21(12):2148-2159.
19. Wang H, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23(3):668-681.
20. Liu HN, et al. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J Neurosci. 2012;32(26):8791-8799.
21. Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 2010;113(5):1188-1199.
22. Winer L, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70(2):201-207.
23. Ong SE. The expanding field of SILAC. Anal Bioanal Chem. 2012;404(4):967-976.
24. Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264(5166):1772-1775.
25. Aoki M, Kato S, Nagai M, Itoyama Y. Development of a rat model of amyotrophic lateral sclerosis expressing a human SOD1 transgene. Neuropathology. 2005;25(4):365-370.
26. Borchelt DR, et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci U S A. 1994;91(17):8292-8296.
27. Hoffman EK, Wilcox HM, Scott RW, Siman R. Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. J Neurol Sci. 1996;139(1):15-20.
28. Ratovitski T, et al. Variation in the biochemical/ biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum Mol Genet. 1999;8(8):1451-1460.
29. Johnston JA. Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2000;97(23):12571-12576.
30. Oeda T, et al. Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. Hum Mol Genet. 2001;10(19):2013-2023.
31. DeVos SL, Miller TM. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics. 2013;10(3):486-497.
32. Savas JN, Toyama BH, Xu T, Yates JR, Yates JR 3rd, Hetzer MW. Extremely long-lived nuclear pore proteins in the rat brain. Science. 2012;335(6071):942.
33. Tsvetkov AS, et al. Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. Nat Chem Biol. 2013;9(9):586-592.
34. Barmada SJ, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014;10(8):677-685.
35. Nagai M, et al. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci. 2001;21(23):9246-9254.
36. Chan PH, et al. Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion. J Neurosci. 1998;18(20):8292-8299.
37. Owens FN, Shin IS, Pettigrew JE, Oltjen JW. Apportioning leucine requirements for maintenance versus growth for rats. Nutr Res. 1994;14(1):73-82.
38. Prudencio M, Durazo A, Whitelegge JP, Borchelt DR. An examination of wild-type SOD1 in modulating the toxicity and aggregation of ALS-associated mutant SOD1. Hum Mol Genet. 2010;19(24):4774-4789.
39. Reeds DN, Cade WT, Patterson BW, Powderly WG, Klein S, Yarasheski KE. Whole-body proteolysis rate is elevated in HIV-associated insulin resistance. Diabetes. 2006;55(10):2849-2855.
40. Parise G, Mihic S, MacLennan D, Yarasheski KE, Tarnopolsky MA. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. J Appl Physiol. 2001;91(3):1041-1047.